Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery and Advance Clinical Trials
5 Sources
[1]
Alphabet's Isomorphic Labs raises $2.1bn in Series B funding
The organisation plans to use the investment as a means of accelerating the application of its AI model, at scale. AI-powered drug design and development company Isomorphic Labs has announced the raising of $2.1bn in Series B funding. The round was led by Thrive Capital and includes participation
[2]
Alphabet's Isomorphic Labs reportedly raising $2B+ for its medical research AI - SiliconANGLE
Alphabet's Isomorphic Labs reportedly raising $2B+ for its medical research AI Isomorphic Labs Inc., an Alphabet Inc. unit using artificial intelligence to speed up drug development, is reportedly in talks to raise a new funding round. Sources told Bloomberg today that the investment could be
[3]
Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery
AI drug discovery firm Isomorphic Labs secured a massive $2.1 billion funding round, aiming to accelerate its mission to cure all diseases. Led by Thrive Capital, the investment will scale their drug design engine, with initial clinical trials now anticipated by late 2026. Isomorphic Labs, an
[4]
Google's Isomorphic Labs to raise over $2 billion in new funding - The Economic Times
Alphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. This significant investment aims to bolster its drug design engine and fuel global expansion, underscoring Alphabet's strategy of commercializing its advanced
[5]
Alphabet-Backed Isomorphic Labs Raises $2.1 Billion for AI Drug Development
Isomorphic Labs raised $2.1 billion in its Series B funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. The subsidiary of Google parent Alphabet said Tuesday that U.S. capital venture firm Thrive Capital once again led the funding round, which
Share
Copy Link
Alphabet-backed Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital, with participation from MGX, Temasek, and the UK Sovereign AI Fund. The Google DeepMind spin-off will use the investment to scale its AI drug design engine and expects to begin clinical trials by late 2026, marking a shift from its earlier 2025 target.
Isomorphic Labs Secures $2.1 Billion Series B Funding
Isomorphic Labs announced it has raised $2.1 billion in Series B funding, marking one of the largest investments in AI drug discovery to date
1
. The round was led by Thrive Capital, with participation from existing backers Alphabet and Google Ventures, alongside new investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund3
. This follows the company's $600 million first funding round last year, also led by Thrive Capital3
.
Source: Silicon Republic
Founded in 2021 as a Google DeepMind spin-off, Isomorphic Labs is led by CEO Demis Hassabis, who also helms Google's AI division DeepMind and won half the 2024 Nobel Prize in chemistry for his work on protein structure prediction
2
. The London-based company maintains additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland1
.AI-Powered Drug Design Engine Drives Investment Confidence
The company plans to deploy the capital toward scaling its AI drug design engine, known as IsoDDE, which has already demonstrated significant capabilities in accelerating drug research and development
1
. According to President Max Jaderberg, the AI-powered drug design platform has proven its effectiveness across internal programs by hitting key milestones and identifying viable candidates with unprecedented speed1
.
Source: SiliconANGLE
IsoDDE builds on the AlphaFold AI platform, which can accurately predict protein structures in minutes—a task that historically required years of manual work
5
. The system outperforms even AlphaFold 3 in specific tasks, more than doubling its score on the most difficult challenges in the Runs N' Poses benchmark2
. The technology excels at identifying binding pockets in proteins—entry points through which drugs can be delivered into disease-causing cells—while requiring relatively limited data2
.Clinical Trials Timeline and Pharmaceutical Partnerships
Isomorphic Labs now expects to run its first clinical trials by the end of 2026, a delay from Demis Hassabis's earlier target of having AI-designed drugs in trials by the end of 2025
1
. The revised timeline reflects the company's commitment to scaling its technology to full potential before moving to human trials.The company has already forged partnerships with pharmaceutical companies including Eli Lilly, Johnson & Johnson, and Novartis to advance AI-driven drug development across multiple therapeutic areas
4
5
. These collaborations demonstrate growing industry confidence in applying AI to accelerate research timelines and reduce development costs.Related Stories
Alphabet's Strategy to Commercialize AI Ventures
Ruth Porat, president and chief investment officer at Alphabet and Google, emphasized the profound opportunity AI presents in healthcare. "Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform," Porat stated
1
. The investment represents another step in Alphabet's plan to transform futuristic ventures into standalone businesses, similar to Waymo's $16 billion raise at a $126 billion valuation earlier this year4
.
Source: ET
The funding will support current hiring targets as the company expands its team globally
4
5
. Hassabis described the round as "a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development"5
. With Alphabet's cloud business recently growing 63% to hit $20 billion and consolidated revenue reaching nearly $110 billion, the parent company demonstrates strong financial backing for its AI investments1
.References
Summarized by
Navi
[1]
[2]
[5]
Related Stories
Alphabet's AI Drug Discovery Spin-off Isomorphic Labs Secures $600M in Landmark Funding Round
31 Mar 2025•Business and Economy
Google DeepMind's Isomorphic Labs Nears Human Trials for AI-Designed Drugs
07 Jul 2025•Science and Research
Latent Labs Emerges with $50M to Revolutionize Drug Discovery Using AI
13 Feb 2025•Technology
Recent Highlights
1
OpenAI Claims AI Math Breakthrough on Navier-Stokes, Sparks Controversy Over Credit and Future of Research
Science and Research
2
Anthropic CEO Calls to Slow AI Development Pace After Security Incidents Spark Industry Alarm
Policy and Regulation
3
Nvidia CEO Jensen Huang Declares AGI Has Arrived With OpenAI's GPT-6 Astra Release
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
